Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia

Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia

Author Chaves, Cristiano Google Scholar
Marque, Cristiane R. Google Scholar
Maia-de-Oliveira, Joao P. Google Scholar
Wichert-Ana, Lauro Google Scholar
Ferrari, Thiago B. Google Scholar
Santos, Antonio C. Google Scholar
Araujo, David Google Scholar
Machado-de-Sousa, Joao P. Google Scholar
Bressan, Rodrigo A. Autor UNIFESP Google Scholar
Elkis, Helio Google Scholar
Crippa, Jose A. Google Scholar
Guimaraes, Francisco S. Google Scholar
Zuardi, Antonio W. Google Scholar
Baker, Glen B. Google Scholar
Dursun, Serdar M. Google Scholar
Hallak, Jaime E. C. Google Scholar
Institution Universidade de São Paulo (USP)
Natl Sci & Technol Inst Translat Med INCT TM
Univ Fed Rio Grande do Norte
McGill Univ
Universidade Federal de São Paulo (UNIFESP)
Univ Alberta
Abstract Increasing evidence suggests that the tetracycline antibiotic minocycline has neuroprotective effects and is a potential treatment for schizophrenia. However, the mechanisms of action of minocycline in the CNS remain elusive. the aim of this study was to investigate the effects of minocycline on brain morphology and cerebral perfusion in patients with recent-onset schizophrenia after 12 months of a randomized double-blind, placebo-controlled clinical trial of minocycline add-on treatment. This study included 24 outpatients with recent-onset schizophrenia randomized for 12 months of adjuvant treatment with minocycline (200 mg/d) or placebo. MRI (1.5 T) and [Tc-99m]-ECD SPECT brain scans were performed at the end of the 12-month of trial. Between-condition comparisons of SPECT and MRI brain images were performed using statistical parametric mapping and analyzed by voxel-based morphometry (VBM). Minocycline adjuvant treatment significantly reduced positive and negative symptoms when compared with placebo. the VBM analysis of MRI scans showed that the patients in the placebo group had significant lower gray matter volumes in the midposterior cingulate cortex and in the precentral gyrus in comparison with the patients in the minocycline group. in addition, a decreased ECD uptake in the minocycline condition was observed in fronto-temporal areas. These results suggest that minocycline may protect against gray matter loss and modulate fronto-temporal areas involved in the pathophysiology of schizophrenia. Furthermore, minocycline add-on treatment may be a potential treatment in the early stages of schizophrenia and may ameliorate clinical deterioration and brain alterations observed in this period. (C) 2014 Elsevier B.V. All rights reserved.
Keywords Schizophrenia
Language English
Sponsor Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Grant number CNPq: 302453/2011-3
Date 2015-02-01
Published in Schizophrenia Research. Amsterdam: Elsevier B.V., v. 161, n. 2-3, p. 439-445, 2015.
ISSN 0920-9964 (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 439-445
Origin http://dx.doi.org/10.1016/j.schres.2014.11.031
Access rights Closed access
Type Article
Web of Science ID WOS:000348452100044
URI http://repositorio.unifesp.br/handle/11600/38705

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account